🔥 What This Document Is

This is a 6-K report from Galapagos NV, a Belgian biotech company listed on Euronext and NASDAQ (ticker: GLPG). It’s a current report used to announce major events to investors. This specific filing announces a new, binding collaboration deal with pharmaceutical giant Gilead Sciences.

👉 In simple terms: It’s a press release filed with the SEC to tell the world, "We've just restructured a major deal with a big partner. Here's what it means for our company, our money, and our future."

🏢 What The Company Does

Galapagos NV is a biotechnology company. They don't just invent new drugs; they are a "dealmaker" biotech.

👉 In simple terms: Think of them as a scout and developer for cutting-edge medicines. They use their capital and expertise to find promising drug candidates from smaller labs or companies, fund and manage their development, and then partner with big pharma (like Gilead) to handle late-stage trials and global sales. Their focus is on oncology (cancer) and immunology & inflammation.

💰 Financial Highlights of the Deal

This is all about how money and costs are split with Gilead for a drug called gamgertamig.

• 💰 The Big Purchase: Gilead is buying Ouro Medicines (the company that owns gamgertamig) for $1.675 billion upfront and up to $500 million in future milestone payments.
• 🤝 Galapagos's Share: Galapagos gets 50% of that upfront cash and 50% of the future milestones. This is part of the new, "meaningfully improved" terms.
• 💸 Galapagos Pays For: They will fund all development costs until the drug starts its final "registrational" (Phase 3) studies. After that, Gilead and Galapagos split costs 50/50.
• 📈 Galapagos Earns: Once the drug is sold, Gilead will pay Galapagos royalties between 20-23% on net sales. They can also get up to $100 million in extra milestones if Gilead starts trials in certain other diseases.

🚀 The Star of the Show: Gamgertamig

This is the drug driving the entire deal. It's called a T-cell engager.

👉 In simple terms: Imagine your immune system's T-cells are soldiers. Gamgertamig is like a specialized guide that grabs onto bad, disease-causing immune cells (pathogenic B-cells and plasma cells) and brings the T-cell soldiers right to them to destroy them. This could "reset" the immune system in autoimmune diseases.

• 🔬 Stage: It's in Phase 1b clinical trials right now.
• 🎯 Target: For autoimmune diseases like Autoimmune Hemolytic Anemia (AIHA) and Immune Thrombocytopenia (ITP).
• 🌟 Potential: It's considered "first-in-class" and "best-in-class." Early data shows it can lead to deep, durable remissions after a short course of treatment. The U.S. FDA has given it Fast Track and Orphan Drug Designation for AIHA and ITP.

⚖️ Why This Structure Matters (The OLCA Waiver)

This is a crucial, but complex, part of the deal. Galapagos had an old 10-year agreement with Gilead (from 2019) that limited its strategic options.

• 🔓 The Change: As part of this new deal, Gilead is granting a waiver. This frees up $500 million of Galapagos's cash that can now be used completely independently of Gilead.
• 🎯 What They Can Do With It: This money can be used to buy or develop other drug programs not involving Gilead. They can also use up to $150 million of it for share buybacks or returning capital to shareholders.
• 👉 Why it's huge: It gives Galapagos major strategic and financial flexibility. They are no longer tied only to Gilead for future deals. The majority of their cash pile remains available for other opportunities.

🔮 What's Next & The Broader Pipeline

• 📅 Key Date: Gilead's purchase of Ouro is expected to close in Q2 2026. The Galapagos collaboration starts then.
• 🚀 Drug Timeline: Galapagos expects gamgertamig to enter registrational studies as early as 2027. They will release clinical data throughout 2026.
• 🧪 Beyond Gamgertamig: The deal also gives Galapagos rights to three additional preclinical autoimmune programs. Gilead has an option to opt into a 50/50 profit split on each after they prove effective, paying $75 million per program.

⚖️ Big Picture: Strengths & Risks

👍 Strengths / Why This is a Good Move:

• Acquires a de-risked, high-potential asset with strong early data.
• Keeps the majority of its cash ($500M+) for future deals or capital returns.
• Shares the high costs and risks with a giant partner (Gilead).
• Earns potentially significant royalties from a blockbuster-candidate drug.
• Gains a clinical development team from Ouro, building internal capabilities.

⚠️ Risks / What to Watch For:

• Execution Risk: Galapagos is now responsible for funding and leading expensive development until Phase 3. Any delays or failures increase their costs.
• Clinical Risk: Gamgertamig is still in early trials. It must succeed in larger, later-stage studies.
• Market Competition: The field of T-cell engagers for autoimmunity is new and rapidly developing. Other competitors could emerge.
• Related Party Complexity: Gilead owns about 25% of Galapagos. This deal was approved by a special committee of independent directors, highlighting the need for careful governance.

🧠 The Analogy

This deal is like Galapagos leasing a powerful, prototype sports car (gamgertamig) from a master builder (Gilead/Ouro). Galapagos pays the early maintenance and tuning costs (pre-Phase 3 development). In return, they get the first right to drive it in certain races (other indications), a cut of the future prize money (royalties), and—critically—the cash to go buy their own workshop and build other cars independently (the $500M waiver). The master builder handles the global racing team (commercialization).

📇 Key Contacts & People

Galapagos NV:

• Henry Gosebruch, Chief Executive Officer
• Sherri Spear, Investor Relations & Media
  • Phone: +1 412 522 6418
  • Email: [email protected]

Ouro Medicines:

• Jaideep Dudani, PhD, Co-Founder and Chief Executive Officer

Gilead Sciences, Inc.:

• Andrew Dickinson, Chief Financial Officer

Advisors to Galapagos:

• Financial Advisor: Morgan Stanley & Co., LLC
• Legal Counsel: Paul, Weiss, Rifkind, Wharton & Garrison LLP and Linklaters LLP
• Independent Financial Advisor (to the Board Committee): MTS Health Partners, L.P.

🧩 Final Takeaway

Galapagos is transforming itself from a partner-dependent biotech into a more independent "dealmaker and developer." This deal gives them a cutting-edge drug, a deep financial partner in Gilead, and—most importantly—the $500 million freedom to pursue other opportunities. It's a strategic pivot that balances significant upside potential with shared risk.